ArticleBMJ public health2025
Rift Valley fever seroprevalence and risk factors among human populations in Uganda's cattle corridor: a cross-sectional study.
Article in BMJ public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Rift Valley fever (RVF) is an epidemic-prone zoonotic disease whose distribution of exposure is poorly described in endemic communities. We investigated the seroprevalence and risk factors for RVF among humans in Uganda's cattle corridor. Methods: This cross-sectional study used data and stored plasma specimens collected by the Uganda population-based HIV impact assessment (UPHIA) survey 2016/2017. Participants were sampled from 35 districts of the cattle corridor. Ethical and regulatory approvals were obtained to use the UPHIA data and to test the specimens for the presence of RVF anti-Gn glycoprotein immunoglobulin G (anti-Gn IgG) antibodies using an enzyme linked immunosorbent Assay (ELISA). RVF seroprevalence was calculated in Stata with household as the random intercept, and associations between potential determinants and RVF seropositivity were assessed using mixed effects logistic regression analysis. Results: Overall, 267 households comprising 1319 individuals were included in the analysis. Over half (56.3%) of the participants were female, median age 22 (IQR 11-34) years. Most (84.2%) were rural and owned cattle (41.2%), sheep/goats (51.7%) and poultry (65%). The overall RVF seroprevalence was 10.24%, 95% CI 8.63% to 12.10%. RVF seropositivity was associated with advanced age (25-44 years adjusted OR 2.79 (95% CI 1.81 to 4.32); and 45-64 years (3.0 (95% CI 1.76 to 5.14)); ethnicity (Iteso 2.54 (95% CI 1.15 to 5.62), Langi 2.61 (95% CI 1.20 to 5.66) and Karamojong 3.70 (95% CI 1.61 to 8.47)); owning cattle (1.59 (95% CI 1.03 to 2.45)) and owning poultry (1.73 (95% CI 1.05 to 2.87)). Conclusions: RVF seropositivity is common among humans in Uganda's cattle corridor and the risk of exposure is mostly determined by increasing age, ethnicity, owning cattle and poultry. Future RVF seroprevalence and risk evaluation studies should include poultry as potential determinants of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.